141 related articles for article (PubMed ID: 20025598)
21. Modulation of drug (metoprolol succinate) release by inclusion of hydrophobic polymer in hydrophilic matrix.
Siddique S; Bose A; Khanam J
Drug Dev Ind Pharm; 2011 Sep; 37(9):1016-25. PubMed ID: 21401340
[TBL] [Abstract][Full Text] [Related]
22. Development of sustained-release matrix tablets of BKP-01-041 (tilorone derivative) containing Hypromellose.
Chen L; Wang F
Pharmazie; 2013 Oct; 68(10):796-9. PubMed ID: 24273882
[TBL] [Abstract][Full Text] [Related]
23. Identification of critical formulation and processing variables for metoprolol tartrate extended-release (ER) matrix tablets.
Rekhi GS; Nellore RV; Hussain AS; Tillman LG; Malinowski HJ; Augsburger LL
J Control Release; 1999 Jun; 59(3):327-42. PubMed ID: 10332064
[TBL] [Abstract][Full Text] [Related]
24. Formulation and in-vitro evaluation of floating bilayer tablet of lisinopril maleate and metoprolol tartrate.
Ijaz H; Qureshi J; Danish Z; Zaman M; Abdel-Daim M; Hanif M; Waheed I; Mohammad IS
Pak J Pharm Sci; 2015 Nov; 28(6):2019-25. PubMed ID: 26639495
[TBL] [Abstract][Full Text] [Related]
25. Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets.
Zhao N; Zidan A; Tawakkul M; Sayeed VA; Khan M
Int J Pharm; 2010 Nov; 401(1-2):25-31. PubMed ID: 20849940
[TBL] [Abstract][Full Text] [Related]
26. Optimization of propranolol HCl release kinetics from press coated sustained release tablets.
Ali AA; Ali AM
Pharm Dev Technol; 2013; 18(5):1238-46. PubMed ID: 22582904
[TBL] [Abstract][Full Text] [Related]
27. Development of a modified-release pellets formulation--with metoprolol tartrat and kinetic aspects of in vitro release.
Todoran N; Ciurba A; Al Hussein S; Lazar L; Ion V; Antonoaea P
Rev Med Chir Soc Med Nat Iasi; 2014; 118(4):1143-9. PubMed ID: 25581981
[TBL] [Abstract][Full Text] [Related]
28. Influence of soluble and insoluble cyclodextrin polymers on drug release from hydroxypropyl methylcellulose tablets.
Zugasti ME; Zornoza A; Goñi Mdel M; Isasi JR; Vélaz I; Martín C; Sánchez M; Martínez-Ohárriz MC
Drug Dev Ind Pharm; 2009 Oct; 35(10):1264-70. PubMed ID: 19555243
[TBL] [Abstract][Full Text] [Related]
29. In vitro release of ketoprofen from hydrophilic matrix tablets containing cellulose polymer mixtures.
Vueba ML; Batista de Carvalho LA; Veiga F; Sousa JJ; Pina ME
Drug Dev Ind Pharm; 2013 Nov; 39(11):1651-62. PubMed ID: 23094867
[TBL] [Abstract][Full Text] [Related]
30. Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose.
Huang Y; Khanvilkar KH; Moore AD; Hilliard-Lott M
Drug Dev Ind Pharm; 2003 Jan; 29(1):79-88. PubMed ID: 12602495
[TBL] [Abstract][Full Text] [Related]
31. Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets.
Maboos M; Yousuf RI; Shoaib MH; Nasiri I; Hussain T; Ahmed HF; Iffat W
Lipids Health Dis; 2018 Jun; 17(1):136. PubMed ID: 29885655
[TBL] [Abstract][Full Text] [Related]
32. Development of sustained release capsules containing "coated matrix granules of metoprolol tartrate".
Siddique S; Khanam J; Bigoniya P
AAPS PharmSciTech; 2010 Sep; 11(3):1306-14. PubMed ID: 20721649
[TBL] [Abstract][Full Text] [Related]
33. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices.
Bravo SA; Lamas MC; Salamón CJ
J Pharm Pharm Sci; 2002; 5(3):213-9. PubMed ID: 12553888
[TBL] [Abstract][Full Text] [Related]
34. Formulation Development and Optimization of Matrix Tablet of Tramadol Hydrochloride.
Deb P; Singha J; Chanda I; Chakraborty P
Recent Pat Drug Deliv Formul; 2017; 11(1):19-27. PubMed ID: 27712568
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of injection moulding as a pharmaceutical technology to produce matrix tablets.
Quinten T; De Beer T; Vervaet C; Remon JP
Eur J Pharm Biopharm; 2009 Jan; 71(1):145-54. PubMed ID: 18511248
[TBL] [Abstract][Full Text] [Related]
36. Design and in vitro evaluation of zidovudine oral controlled release tablets prepared using hydroxypropyl methylcellulose.
Ravi PR; Ganga S; Saha RN
Chem Pharm Bull (Tokyo); 2008 Apr; 56(4):518-24. PubMed ID: 18379101
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure.
Wikstrand J; Andersson B; Kendall MJ; Stanbrook H; Klibaner M
J Cardiovasc Pharmacol; 2003 Feb; 41(2):151-7. PubMed ID: 12548073
[TBL] [Abstract][Full Text] [Related]
38. Formulation and in vitro evaluation of ofloxacin-ethocel controlled release matrix tablets prepared by wet granulation method: influence of co-excipients on drug release rates.
Shah S; Shah K; Jan SU; Ahmad K; Rehman A; Hussain A; Khan GM
Pak J Pharm Sci; 2011 Jul; 24(3):255-61. PubMed ID: 21715257
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations.
Rekhi GS; Eddington ND; Fossler MJ; Schwartz P; Lesko LJ; Augsburger LL
Pharm Dev Technol; 1997 Feb; 2(1):11-24. PubMed ID: 9552427
[TBL] [Abstract][Full Text] [Related]
40. Characterization of 5-fluorouracil release from hydroxypropylmethylcellulose compression-coated tablets.
Wu B; Shun N; Wei X; Wu W
Pharm Dev Technol; 2007; 12(2):203-10. PubMed ID: 17510892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
